Clostridium difficile vaccine - sanofi pasteur

Drug Profile

Clostridium difficile vaccine - sanofi pasteur

Alternative Names: ACAM Cdiff; ACAM-CDIFF; CdVax; Clostridium difficile toxoid vaccine - sanofi pasteur

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator Acambis
  • Developer Sanofi Pasteur
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Clostridium infections
  • New Molecular Entity No

Highest Development Phases

  • Phase III Clostridium infections

Most Recent Events

  • 26 Oct 2016 Efficacy and adverse events data from a phase II extension trial in Clostridium infections (Prevention)released by Sanofi
  • 25 Jun 2015 No recent reports of development identified - Phase-II for Clostridium infections in USA and United Kingdom (IM)
  • 12 Jun 2014 Sanofi Pasteur completes a phase I/II trial in Clostridium infections (prevention) in Japan (NCT01896830)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top